Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Jazz Pharmaceuticals plc - Ordinary Shares
(NQ:
JAZZ
)
233.31
+18.88 (+8.80%)
Delayed Quote
Updated: 11:23 AM EST, Nov 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Jazz Pharmaceuticals plc - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
JAZZ Q3 deep dive: oncology momentum and new launches offset margin pressure
Today 0:33 EST
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) beat Wall Street’s revenue expectations in Q3 2026, with sales up 10.4% year on year to $1.24 billion. T...
Via
StockStory
Jazz (JAZZ) Q3 2026 Earnings Call Transcript
↗
November 02, 2026
Oncology portfolio surges 35% as Ziihera launches and Xywav sustains momentum.
Via
The Motley Fool
Topics
Earnings
Jazz Pharmaceuticals Q3 Earnings Call Highlights
↗
November 02, 2026
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported record third-quarter revenue of $1.24 billion, up 10% from a year earlier, and raised its full-year 2026 revenue outlook as growth in its sleep and oncology...
Via
MarketBeat
Topics
Cannabis
Earnings
Jazz Pharmaceuticals (NASDAQ:JAZZ) Q3 Results In Line as Raised Guidance Sparks After-Hours Surge
↗
November 02, 2026
Via
Chartmill
Cannabis Stocks’ Rally Is Narrow as Profitable Healthcare and Consumer Names Do the Heavy Lifting
↗
October 22, 2026
Via
Chartmill
Topics
Cannabis
Jazz Pharmaceuticals (NASDAQ:JAZZ): An Undervalued Biopharma Value Stock
↗
October 09, 2026
Via
Chartmill
Cannabis Stocks Aren’t a Recovery Trade: Narrow Leadership Splits Quality and Momentum
↗
October 06, 2026
Via
Chartmill
Topics
Cannabis
Jazz Pharmaceuticals (NASDAQ:JAZZ) surprises with Q3 2026 sales, full-year sales guidance is optimistic
November 02, 2026
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) beat Wall Street’s revenue expectations in Q3 2026, with revenue rising 10.4% year on year to $1.24 bill...
Via
StockStory
What to expect from Jazz Pharmaceuticals’s (JAZZ) Q3 earnings
October 31, 2026
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting results this Monday after market hours. Here’s what to expect. Jazz Pharmaceuticals be...
Via
StockStory
Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth Engine
↗
October 27, 2026
Jazz Pharmaceuticals' strategy is starting to pay dividends.
Via
The Motley Fool
3 Healthcare Stocks That Concern Us
October 16, 2026
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...
Via
StockStory
Cannabis Stocks: A Profitability Turnaround Is Brewing Beneath Weak Price Action
↗
September 22, 2026
Via
Chartmill
Topics
Cannabis
Jazz Pharmaceuticals (NASDAQ:JAZZ): A Decent Value Stock Trading Below Its Worth
↗
September 02, 2026
Via
Chartmill
Cannabis Rally Turns Selective as Investors Reward Pharma-Tinged Names
↗
August 29, 2026
Via
Chartmill
Topics
Cannabis
3 of Wall Street’s Favorite Stocks That Fall Short
October 14, 2026
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
Via
StockStory
Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks
September 29, 2026
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NAS...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B
↗
September 20, 2026
Jazz Pharmaceuticals (NASDAQ:JAZZ) executives outlined the company’s oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the...
Via
MarketBeat
Topics
Cannabis
Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands
↗
September 20, 2026
Jazz Pharmaceuticals (NASDAQ:JAZZ) outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the...
Via
MarketBeat
Topics
Cannabis
Jazz Pharmaceuticals (NASDAQ:JAZZ): A Decent Value Opportunity
↗
August 12, 2026
Via
Chartmill
Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?
↗
September 18, 2026
Actio could make Jazz's growing epilepsy franchise even stronger.
Via
The Motley Fool
3 Cash-Producing Stocks We’re Skeptical Of
September 11, 2026
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Via
StockStory
Topics
Retirement
2 Reasons to Avoid JAZZ and 1 Stock to Buy Instead
September 11, 2026
Jazz Pharmaceuticals’s 29.7% return over the past six months has outpaced the S&P 500 by 17%, and its stock price has climbed to $240.49 per share. This was ...
Via
StockStory
Topics
Stocks
1 Value Stock with Exciting Potential and 2 We Brush Off
September 08, 2026
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t...
Via
StockStory
Topics
Energy
Retirement
Stocks making big moves yesterday: Jazz Pharmaceuticals, SAIC, Herbalife, AGCO, and Deere
September 01, 2026
Check out the companies making headlines yesterday: Jazz Pharmaceuticals (NASDAQ:JAZZ): Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) rose by 2.5% on ...
Via
StockStory
Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why
August 31, 2026
What Happened? Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 2.5% in the afternoon session after the company announced positive Phase...
Via
StockStory
Topics
Artificial Intelligence
Jazz Pharmaceuticals Launches Ziihera After FDA Nod in HER2-Positive GEA
↗
August 25, 2026
Jazz Pharmaceuticals (NASDAQ:JAZZ) outlined its plans for the U.S. launch of Ziihera following FDA approval of the therapy for first-line HER2-positive unresectable, locally advanced or metastatic...
Via
MarketBeat
Topics
Cannabis
3 Profitable Stocks with Questionable Fundamentals
August 14, 2026
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...
Via
StockStory
Topics
Economy
Jazz Pharmaceuticals (JAZZ) Q2 2026 Earnings Call Transcript
↗
August 10, 2026
Revenue hit $1.2 billion with oncology sales surging and Xywav demand accelerating.
Via
The Motley Fool
Topics
Earnings
5 Revealing Analyst Questions From Jazz Pharmaceuticals’s Q2 Earnings Call
August 10, 2026
Jazz Pharmaceuticals delivered a positive Q2, with a strong 16% year-over-year revenue increase driven primarily by its oncology and rare disease portfolios....
Via
StockStory
Topics
Earnings
Jazz Pharmaceuticals Q2 Earnings Call Highlights
↗
August 03, 2026
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported second-quarter 2026 revenue of $1.21 billion, up 16% from a year earlier, as growth across its sleep, epilepsy and oncology portfolios drove record quarterly...
Via
MarketBeat
Topics
Cannabis
Earnings
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
